Nexavar Works for Liver Cancer, But It Isn’t Cheap

The study of Nexavar for liver cancer that was the talk of last year’s ASCO conference gets its closeup this week, with publication of the full results in the New England Journal of Medicine. The basic findings are the same as they were at ASCO: In patients with late-stage disease, median survival was 10.7 months [...]